Market news: Novo Nordisk announced the latest developments in the ZEUS phase III clinical trial, which targets patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.